Expression of epirdermal growth factor receptor as a predictive factor for rectal cancer

Archives of Iranian Medicine

Volumn 10, Issue 3, 2007, Pages 301-308

  Motlagh, Ali ^a,b   Azadeh, Payam ^a   Fazlalizadeh, Abdolah ^a   Shahrad, Behrouz ^a   Shafaghi, Behrouz ^b   Fudazi, Mohammad ^c   Tosefi, Amirshahram ^a   Davaei, Manoochehr ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Khatamolanbia Hospital   (Iran)

Author keywords

Colorectal cancer; Epidermal growth factor receptor (EGFR); Sphincter preserving

Indexed keywords

COBALT 60; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANUS SPHINCTER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; COBALT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PELVIS RADIOGRAPHY; PHYSICAL EXAMINATION; PREOPERATIVE TREATMENT; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RADIATION DOSE; RECTUM BIOPSY; RECTUM CANCER; RECTUM CARCINOMA; RECTUM SURGERY; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; ANAL CANAL; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RADIATION DOSE FRACTIONATION; RECTUM TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANAL CANAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 34547458136     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Garfinkel L, Cancer statistics and trends. In: Holleb AI, Fink DJ, Murphy GP, eds. American Cancer Society Textbook of Clinical Oncology. 1st ed. Atlanta: American Cancer Society; 1991: 1-6.
2. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
3. Minsky B, Cohen A, Kemeny N. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol. 1992; 10: 79-84.
4. Berger C, Muret A, Garaud P, Chapet S, Bourlier P, Reynaud-Bouqnoux A, et al. Preoperative radiotherapy for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density: prognostic implications. Int J Radiat Oncol Biol Phys. 1997; 37: 619-627.
5. Calvo FA, Gomez-Espi M, Diaz-Gonzalez JA, Cantalapiedra R, Marcos P, Alvarado A, et al. Pathologic downstaging of rectal cancer after chemoradiation: 5-fluorouracil vs. tegafur. Int J Radiat Oncol Biol Phys. 2001; 51: 1264-1270.
6. Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999; 51: 153-160.
7. Janjan NA, Crane C, Feig BW. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. J Am J Clin Oncol. 2000; 47: 713-718.
8. Mohiuddin M, Hayne M, Regine WF. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys. 2000; 48: 1075-1080.
9. Ruo L, Tickoo S, Klimstra DS. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002; 236: 75-81.
10. Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi A, et al. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectom. 2005; 48: 1851-1857.
11. Giralt J, Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol. 2005; 74: 101-108.
12. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005; 16: 102-108.
13. Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, et al. Prognostic impact of epidermal growth factor receptor (EGFR) expression on locoregional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer. 2005; 5: 62.
14. Steele RJC, Kelly P, Ellul B. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg. 1990; 77: 1352-1354.
15. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988; 48: 137-141.
16. Mayer A, Takimoto M, Fritz E. The prognostic significance of proliferation cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993; 71: 2454-2460.
17. Carperter G. Receptors for epidermal growth factor and other polypeptide mitogens. Ann Rev Biochem. 1987; 56: 881-914.
18. Marco ED, Pierce JH, Fleming TP. Autocrine interaction between TGF-α and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene. 1992; 4: 831-838.
19. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, et al. Activated extracellular signal-regulated kinases. Association with epidermal growth factor receptor/transforming growth factor a expression in head-and-neck squamous cell carcinoma and inhibition by antiepidermal growth factor receptor treatments. Cancer Res. 2001; 61: 1-11.
20. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal growth factor receptor as predictor of early recurrence of and death from breast cancer. Lancet. 1987; 1: 1398-1402.
21. Nicholson S, Halcrow P, Sainsbury JR, Angus B, Chambers P, Farndon JR, et al. Epidermal growth factor receptor status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer. 1988; 58: 810-814.
22. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90: 824-832.
23. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001; 93: 1246-1256.
24. Giralt J, Eraso A, Armengol M, Rossello J, Majo J, Ares C, et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 54: 1460-1465.
25. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73: 2680-2686.
26. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinomas. Cancer Res. 2002; 62: 7350-7356.
27. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen- independence in human prostate cancer. Clin Cancer Res. 2002; 8: 3438-3444.
28. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res. 1995; 1: 19-31.
29. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma. Cancer. 2001; 92: 1331-1346.
30. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastases. Eur J Cancer. 2002; 38: 2258-2264.
31. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003; 97: 960-968.
32. Lammering G, Hewit TH, Hawkins WT, Contessa. JN, Reardon DB, Lin PS, et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 2001; 93: 921-929.
33. Petersen C, Eicheler W, Frommel A, Krause M, Balschukat S, Zips D, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol. 2003; 79: 469-477.
34. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TP. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinomas to chemotherapy. Cancer. 1994; 74: 1693-1698.
35. Bensadoun RJ, Magne N, Marcy PY. BID radiotherapy and chemotherapy with CDDP/5-FU in unresectable pharyngeal carcinoma: 10 years experience at the Center Antoine-Lacassagne. Impact of tumoral EGFR level in response and survival. Proceedings of the 43rd American Society for Therapeutic Radiation Oncology (ASTRO) meeting. Int J Radiat Oncol Biol Phys. 2001; 51 (suppl 1): 39-40.
36. Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998; 37: 285-289.
37. Skibber JM, Minsky BD, Hoff PM. Cancer of the colon. Cancers of the gastrointestinal tract. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001: 1216-1271.
38. Tong WM, Ellinger A, Sheinin Y Cross HS. Epidermal growth factor receptor expression in primary cultured human colorectal carcinoma cells. Br J Cancer. 1998; 77: 1792-1798.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
40. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase with prognosis of human colorectal carcinomas. Jpn J Clin Oncol. 1995; 25: 240-249.
41. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001; 37 (suppl 4): S9-S15.
42. De Jong KP, Stellema R, Karrenbeld A. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998; 28: 971-979.
43. Takemura K, Obara T, Okano S, Yokota K, Ura H, Saitoh Y, et al. Immunohistochemical study on the expression of epidermal growth factor receptor (EGFR) in human colorectal carcinomas [in Japanese]. Nippon Shokakibyo Gakkai Zasshi. 1991; 88: 1177-1183.
44. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ, Davis NL. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992; 1: 97-105.
45. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology. 1994; 25: 455-461.
46. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998; 55: 548-555.
47. Kapitanovic S, Radosevic S, Kapitanovic M. The expression of p185 (HER-2/ neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997; 112: 1103-1113.
48. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005; 62: 752-760.
49. Bouzourene H, Bosman F, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy Cancer. 2002; 94: 1121-1130.